Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2007-11-13
2007-11-13
Mondesi, Robert (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C424S078080
Reexamination Certificate
active
10758572
ABSTRACT:
The subject invention provides a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a peptide having the structural formulain-line-formulae description="In-line Formulae" end="lead"?NH2-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-COOH;in-line-formulae description="In-line Formulae" end="tail"?and a substituted β-cyclodextrin in an amount effective to dissolve the peptide in the aqueous carrier, wherein the composition has a pH between 4 and 9, a process for preparation, and a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject the pharmaceutical composition.
REFERENCES:
patent: 4656158 (1987-04-01), Matsuo et al.
patent: 5126249 (1992-06-01), Becker et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5376645 (1994-12-01), Stella et al.
patent: 5646131 (1997-07-01), Badwan et al.
patent: 5997856 (1999-12-01), Hora et al.
patent: 6228363 (2001-05-01), Naparstek
patent: 6407079 (2002-06-01), Muller et al.
patent: 6613536 (2003-09-01), Mozes et al.
patent: 2002/0054872 (2002-05-01), Napastek
patent: 2004/0127408 (2004-07-01), Mozes
patent: 2005/0008634 (2005-01-01), Cohen-Vered et al.
patent: 0495049 (1992-07-01), None
patent: WO9630057 (1996-10-01), None
patent: WO9931066 (1999-06-01), None
patent: WO03067848 (2002-09-01), None
Anderson, B.D. and Flora, K.P. “The Practice of Medicinal Chemistry” (Chapter 34, pp. 739-754, edited by Camille Georges Wermuth, Academic Press 1996.
U.S. Appl. No. 10/758,397, filed Jan. 14, 2004, Sharon Cohen-Vered et al.
Audibert et al. (1981) Active antitoxic immunization by a diphtheria toxin synthetic oligopeptide.Nature, 289:593-4.
Axelrod, O. and Mozes, E. (1986) Analysis of the biological functions and fine specificity of (T,G)-A-L specific T cell clones.Immunobiology, 172:99-109.
Bombardier C. et al. (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.Arthritis Rheum., 35:630-40.
Conlon, P.J. (1983) A rapid biologic assay for the detection of interleukin I.J. Immunol., 134:1280-2.
Dayan M. et al. (2000) Immune response of SLE patients to peptides based on the complementarity determining regions of a pathogenic anti-DNA monoclonal antibody.J. Clin. Immunol., 20(3):187-94.
Dean G.S. et al. (2000) Cytokines and systemic lupus erythematosus.Ann. Rheum. Dis., 59:243-51.
Eilat, E., et al. (2000) Prevention of systemic lupus erythematosus-like disease in (NZB×NZW)F1 mice by treating with CDR1- and CDR3- based peptides of pathogenic autoantibody.J. Clin. Immunol., 20:268-78.
Eilat, E., et al. (2001) The mechanism by which a peptide based on complementarity determining region-1 of pathogenic anti-DNA antibody ameliorates experimental SLE.Proc. Natl. Acad. Sci. U.S.A., 98: 1148-53.
Fricke, H. et al. (1991) Idiotype specific T-cell lines inducing experimental systemic lupus erythematosus in mice.Immunology, 73:421-7.
Fricke, H. et al. (1990) Induction of experimental systemic lupus erythematosus in mice by immunization with a monoclonal anti-La autoantibody.Int. Immunol., 2:225-30.
Gearing, A.J.H. et al. (1994) Processing of tumor necrosis factor-alpha precursor by metalloproteinases.Nature, 370:555-7.
Gijbels, K. et al. (1992) Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders.J. Neuroimmunol., 41:29-34.
Goetzl, E.J. et al. (1996) Matrix metalloproteinases in immunity.J. Immunol., 156:1-4.
Guedez, L. et al. (1996) The role of metalloproteinases and their inhibitors in hematological disorders.Crit. Rev. Oncog., 7:205-25.
Hay, E.M. et al. (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.O. J. Med., 86:447-58.
Isenberg, D.A., et al. (1984) Anti-DNA antibody idiotypes in systemic lupus erythematosus.Lancet, 2(8400):417-22.
Isenberg, D.A., et al. (1985) Detection of cross-reactive anti-DNA antibody idiotypes on renal tissue-bound immunoglobulins from lupus patients.J. Clin. Invest., 76(1):287-94.
Katchalski, E. et al. (1955) Molecular weight distribution of linear and multichain polyamino acids. Statistical analysis.J. Am. Chem. Soc., 77:6175-82.
Kotajima, L., et al., (1998) Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis.Clin. Exp. Rheumatol., 16(4):409-15.
Mendlovic, S. et al. (1988) Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype.Proc. Natl. Acad. Sci. U.S.A., 85:2260-4.
Mendlovic, S. et al. (1989) The role of anti-idiotypic antibodies in the induction of experimental systemic lupus erythematosus in mice.Eur. J. Immunol., 19:729-34.
Mendlovic, S. et al. (1990) The genetic regulation of the induction of experimental SLE.Immunology, 69:228-36.
Mozes, E. et al. (1989) Direct binding of a myasthenia gravis related epitope to MHC class II molecules on living murine antigen-presenting cells.EMBO J., 8:4049-52.
Muller, G.M. et al. (1982) Anti-influenza response achieved by immunization with a synthetic conjugate.Proc. Natl. Acad. Sci. U.S.A., 79:569-73.
Nakamara, T. et al. (1993) Gene expression of metalloproteinases and their inhibitor in renal tissue of New Zealand black/white F1 mice.Clin. Sci., 85:295-301.
Paemen, L. et al. (1994) Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases.Eur. J. Neurol., 1:55-63.
Ruiz, P.J. et al. (1994) Induction of experimental systemic lupus erythematosus in mice by immunization with the f(ab)2 fragment of the human anti-DNA monoclonal antibody carrying the 16/6 idiotype.Immunol. Lett., 41:79-84.
Saren, P. et al. (1996) TNF-alpha and IL-1 beta selectively induce expression of 92-kDa gelatinase by human macrophages.J. Immunol., 157:4159-65.
Schnolzer, M. et al. (1992) In situ neutralization in Boc-chemistry solid phase synthesis. Rapid, high yield assembly of difficult sequences.Int. J. Pept. Protein Res., 40: 180-93.
Segal, R. et al. (1997) Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease.J. Immunol., 158:3009-16.
Shoenfeld, Y. et al. (1983) Idiotypic cross-reactions of monoclonal human lupus autoantibodies.J. Exp. Med., 158:718-30.
Shoenfeld, Y. et al. (1982) Production of autoantibodies by human-human hybridomas.J. Clin. Invest., 70:205-8.
Sthoeger, Z.M. et al. (1993) Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome.J. Clin. Immunol., 13:127-38.
Tan, E.M. et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus.Arthritis Rheum., 25:1271-7.
Theofilopoulos, A.N. et al. (1999) Tumour necrosis factor and other cytokines in murine lupus.Ann. Rheum. Dis., 58(Suppl.):149-55.
Waisman, A. et al. (1993) Variable region sequences of autoantibodies from mice with experimental systemic lupus erythematosus.Eur. J. Immunol., 23:1566-73.
Waisman, A. et al. (1995) The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment.Int. Immunol., 7:689-696.
Waisman, A., et al. (1997) Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of pathogenic anti-DNA monoclonal antibodies.Proc. Natl. Acad. Sci. U.S.A., 94(4): 4620-5; and.
Zucker, S. et al. (1999) Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity.J. Rheumatol., 26:78-80.
Brosch N. et al. (2000) A Peptide Based on the Sequence of the CDR3 of a Murine Anti-DNA mAb is a Better Modulator of Experimental SLE than its Single Amino Acid-Substituted Analogs.Cellular Immunology, 205:52-61.
Brosch N. et a
Cohen-Vered Sharon
Gilbert Adrian
Klinger Ety
Naftali Esmira
Weinstein Vera
Cooper & Dunham LLP
Desai Anand
Mondesi Robert
TEVA Pharmaceutical Industries Ltd.
White John P.
LandOfFree
Parenteral formulations of a peptide for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Parenteral formulations of a peptide for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Parenteral formulations of a peptide for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3852401